A carregar...

Bispecific antibodies in cancer immunotherapy

Following the clinical success of immune checkpoint antibodies targeting CTLA-4, PD-1 or PD-L1 in cancer treatment, bispecific antibodies are now emerging as a growing class of immunotherapies with potential to further improve clinical efficacy and safety. We describe three classes of immunotherapeu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ther Adv Vaccines Immunother
Main Authors: Dahlén, Eva, Veitonmäki, Niina, Norlén, Per
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2018
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5933537/
https://ncbi.nlm.nih.gov/pubmed/29998217
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2515135518763280
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!